“放-靶-免”组合在微卫星稳定型晚期结直肠癌三线治疗中的价值初步探索

Preliminary study on the value of"radiation-targeted therapy-immunotherapy"combination in the third-line treatment of microsatellite stable metastatic colorectal cancer

目的:探讨“放-靶-免”联合治疗模式在微卫星稳定型(MSS)晚期结直肠癌患者三线治疗中的临床价值及毒副反应评估。方法:回顾性分析我院肿瘤中心接受上述联合治疗模式的MSS亚型晚期结直肠癌患者,对其治疗疗效及毒副反应进行评估。结果:5例接受“放-靶-免”联合治疗模式的MSS亚型晚期结直肠癌患者中最佳疗效评价为部分缓解的1例,疾病稳定的2例,疾病进展的2例,疾病控制率(DCR)为60.0%(3/5)。而在毒副反应方面,5例患者均未出现III-IV级毒副反应。结论:“放-靶-免”组合模式有望为难治性的MSS亚型的晚期结直肠癌三线治疗提供新的策略,当然该结论仍需要更大的样本量进行验证。

Objective:To investigate the clinical value and side effects of"radiation-targeted therapy-immunotherapy"combined therapy in the third-line treatment of patients with microsatellite stable(MSS)metastatic colorectal cancer(mCRC).Methods:Patients with MSS subtype mCRC who received the above-combined treatment mode in our cancer center were retrospectively analyzed,and the treatment efficacy and side effects were evaluated.Results:Among the 5 patients with MSS subtype mCRC who received the"radiation-target therapy-immunotherapy"combined treatment mode,the efficacy evaluation was the partial response(PR)in 1 case,stable disease(SD)in 2 cases,and progression disease(PD)in 2 cases,with a disease control rate(DCR)of 60.0%(3/5).In terms of side effects,none of the 5 patients had grade III-IV side effects.Conclusion:The"radiation-targeted therapy-immunotherapy"combination mode is expected to provide a new strategy for the third-line treatment of mCRC with refractory MSS subtypes,although this conclusion still needs to be verified with a larger sample size.